Ramoplanin is a potent antibiotic, first disclosed in 1984, that acts by inhibiting bacterial cell-wall biosynthesis. The original ramoplanin complex was shown to consist of a mixture of three closely related compounds, ramoplanin A1-A3, of which ramoplanin A2 is the most abundant. The structure of ramoplanin A2 was unambiguously established first through a series of extensive spectroscopic studies, allowing complete stereochemical assignments and subsequently providing a minor reassignment of the side-chain double-bond stereochemistry and, most recently, through total synthesis of authentic material. Here we report the total syntheses of the aglycons of the minor components of the ramoplanin complex, A1 and A3, which unambiguously establish their structure and provide an expected structural revision for the lipid side-chain double-bond stereochemistry.
Ramoplanin is a lipoglycodepsipeptide with potent antibacterial activity that was isolated from the fermentation broth of Actinoplanes sp. ATCC 33076 as a mixture of three closely related compounds, 1-3, of which 2 is the most abundant ( Fig. 1) (1, 2). Although less extensively studied, the enduracidins represent closely related antibiotics (3, 4), and the uncharacterized antibiotic janiemycin has been reported to bear an amino acid composition and biological properties that suggest it represents an additional member of this class of natural products (5). The ramoplanin complex is 2-10 times more active than vancomycin against Gram-positive bacteria (6) and exhibits a distinct mode of action (7-12), and the ramoplanin A2 aglycon is equally or slightly more potent than the corresponding natural product in antimicrobial assays (13). Ramoplanin has been shown to inhibit bacterial cell-wall biosynthesis by binding and sequestering lipid intermediates I and II (II Ͼ I), thereby preventing the intracellular glycosyltransferase (MurG) and the more accessible extracellular transglycosylase-catalyzed steps of the peptidoglycan assemblage. As a consequence of its unique mechanism of action, cross-resistance with existing antibiotics including vancomycin or the -lactams has not been observed. Ramoplanin is currently in phase III clinical trials for the oral treatment of intestinal vancomycin-resistant Enterococcus faecium and in phase II trials for nasal methicillin-resistant Staphylococcus aureus.Five years after the report of its isolation, the initial structure of ramoplanin was disclosed in 1989. It was established that compounds 1-3 differ only in the acyl group attached to the Asn-1 N terminus (14-17), and the stereochemistry of the two double bonds in the three different acyl groups was assigned as cis-cis (14). In 1991, the structure of a closely related natural product, ramoplanose (4), was disclosed by Williams and coworkers (18), whose composition was identical to ramoplanin A2 with the exception of the branched mannose trisaccharide attached at Hpg 11 and the stereochemistry of the lipid side chain (cis,trans-vs. cis,cis-7-methyloctadi-2,4-enoic acid). Soon t...